Kairos Financial Statements From 2010 to 2025

KAPA Stock   0.74  0.01  1.33%   
Kairos Pharma,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kairos Pharma,'s valuation are provided below:
Market Capitalization
15.7 M
Earnings Share
(0.31)
We have found one hundred four available fundamental ratios for Kairos Pharma,, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Kairos Pharma, last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 29.3 M. The current year's Enterprise Value is expected to grow to about 28.9 M
Check Kairos Pharma, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kairos Pharma,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 127.1 K, Interest Expense of 902 K or Selling General Administrative of 1.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.79. Kairos financial statements analysis is a perfect complement when working with Kairos Pharma, Valuation or Volatility modules.
  
Build AI portfolio with Kairos Stock
Check out the analysis of Kairos Pharma, Correlation against competitors.
For information on how to trade Kairos Stock refer to our How to Trade Kairos Stock guide.

Kairos Pharma, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets6.5 M6.2 M979.8 K
Slightly volatile
Short and Long Term Debt Total454.9 K733.7 K208.9 K
Slightly volatile
Total Current Liabilities1.6 M992 K782.1 K
Slightly volatile
Accounts Payable1.5 M992 K716.3 K
Slightly volatile
Cash1.3 M1.3 M210.5 K
Slightly volatile
Cash And Short Term Investments1.3 M1.3 M210.5 K
Slightly volatile
Common Stock Shares OutstandingM11.4 M11.1 M
Slightly volatile
Liabilities And Stockholders Equity6.5 M6.2 M979.8 K
Slightly volatile
Other Stockholder Equity14.3 M13.6 M2.8 M
Slightly volatile
Total LiabilitiesM1.4 M909.2 K
Slightly volatile
Short and Long Term Debt236.5 K437 K147.7 K
Slightly volatile
Total Current Assets4.4 M4.2 M582.2 K
Slightly volatile
Capital Stock13.3 K14 K135.9 K
Slightly volatile
Short Term Debt3.4 K3.6 K59.1 K
Very volatile
Common Stock13.3 K14 K135.9 K
Slightly volatile
Other Current LiabilitiesM992 K138.1 K
Slightly volatile
Intangible Assets369.6 K222 K621.2 K
Slightly volatile
Non Currrent Assets Other702.5 K1.4 M206.4 K
Slightly volatile
Long Term Debt671 K733.7 K600.5 K
Slightly volatile
Other Current Assets1.6 M2.9 M287.9 K
Slightly volatile

Kairos Pharma, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense902 K859 K162.5 K
Slightly volatile
Selling General Administrative1.4 M1.9 M1.1 M
Slightly volatile
Other Operating Expenses1.7 M2.3 M1.2 M
Slightly volatile
Research Development434.7 K414 K88.8 K
Slightly volatile
Total Operating Expenses1.5 M2.2 M1.2 M
Slightly volatile
Cost Of Revenue158.9 K184 K114.9 K
Slightly volatile

Kairos Pharma, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow139.2 K93 K58.2 K
Slightly volatile
End Period Cash Flow1.3 M1.3 M210.5 K
Slightly volatile
Other Non Cash Items172.4 K254 K163.7 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Payables Turnover0.170.16130.0785
Slightly volatile
Cash Per Share0.120.1120.019
Slightly volatile
Days Payables Outstanding5.5 K6.3 K5.6 K
Pretty Stable
Intangibles To Total Assets0.03660.03850.7415
Slightly volatile
Current Ratio4.414.20260.5875
Slightly volatile
Interest Debt Per Share0.04820.07560.0249
Slightly volatile
Debt To Assets1.430.762.6467
Slightly volatile
Days Of Payables Outstanding5.5 K6.3 K5.6 K
Pretty Stable
Ebt Per Ebit0.981.1111.0718
Slightly volatile
Quick Ratio4.414.20260.5875
Slightly volatile
Net Income Per E B T0.80.90.9812
Slightly volatile
Cash Ratio1.351.28230.2136
Slightly volatile
Debt Ratio1.430.762.6467
Slightly volatile

Kairos Pharma, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap29.3 M19.9 M27.4 M
Slightly volatile
Enterprise Value28.9 M18.4 M27.1 M
Slightly volatile

Kairos Fundamental Market Drivers

About Kairos Pharma, Financial Statements

Kairos Pharma, stakeholders use historical fundamental indicators, such as Kairos Pharma,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although Kairos Pharma, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kairos Pharma,'s assets and liabilities are reflected in the revenues and expenses on Kairos Pharma,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kairos Pharma,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue184 K158.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Kairos Pharma, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kairos Pharma,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kairos Pharma, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kairos Pharma, Stock:
Check out the analysis of Kairos Pharma, Correlation against competitors.
For information on how to trade Kairos Stock refer to our How to Trade Kairos Stock guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kairos Pharma,. If investors know Kairos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kairos Pharma, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.31)
Return On Assets
(0.54)
Return On Equity
(0.92)
The market value of Kairos Pharma, is measured differently than its book value, which is the value of Kairos that is recorded on the company's balance sheet. Investors also form their own opinion of Kairos Pharma,'s value that differs from its market value or its book value, called intrinsic value, which is Kairos Pharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kairos Pharma,'s market value can be influenced by many factors that don't directly affect Kairos Pharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kairos Pharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Kairos Pharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kairos Pharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.